Tyers Asset Management’s Theravance Biopharma TBPH Stock Holding History

Tyers Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$39K	Buy	2,016 +1,400	+227%	+$28.3K	﹤0.01%	926
2019 Q2	$10K	Hold	616	–	–	﹤0.01%	982
2019 Q1	$14K	Hold	616	–	–	﹤0.01%	965
2018 Q4	$16K	Buy	+616	New	+$16.6K	﹤0.01%	924

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Tyers Asset Management's TBPH Position: Q3 2019 in Review

Tyers Asset Management increased its Theravance Biopharma (TBPH) stake by 227% in Q3 2019, buying an estimated $28.3K and bringing the position to 2,016 shares worth $39K. The position accounts for ﹤0.01% of the portfolio, ranked #926.

Tyers Asset Management first reported a position in TBPH in Q4 2018 and has held it in 4 quarters since. 92 funds tracked by Wall St. Rank hold TBPH as of Q3 2019.

Tyers Asset Management held 2,016 shares of Theravance Biopharma worth $39K as of Q3 2019.
Tyers Asset Management bought 1,400 Theravance Biopharma shares in Q3 2019, an estimated $28.3K.
Theravance Biopharma made up ﹤0.01% of Tyers Asset Management's portfolio in Q3 2019, its #926 holding.
Tyers Asset Management first reported a position in Theravance Biopharma in Q4 2018 and has held it in 4 quarters since.
92 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2019.

Based on Tyers Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.